ELYSIA
0551.891.891 · rovalta.com · 24/09/2026
ACTIVE
ELYSIA
Financial year 2025 · closed on 30/06/2025
Net result
129,1 k €
+120.8% YoY
Revenue
12,5 M €
+21.8% YoY
Equity
3,6 M €
+3.7% YoY
Workforce
25,0 ETP
-2.3% YoY
Overview
What does ELYSIA do?
ELYSIA is a Public limited company incorporated in 2014. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Seraing. It employs on average 25,0 ETP workers (FTE).
Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0551.891.891
Incorporation
02/05/2014
Legal form
Public limited company
Registered office
Rue du Bois St-Jean 23
4102 Seraing · WallonieSee on map
4102 Seraing · WallonieSee on map
Contributed capital
4 794 800,00 €
Latest accounts
30/06/2025
Average workforce
25,0 ETP
Activities (NACE)
46460Wholesale of pharmaceutical goods· main46460Wholesale of pharmaceutical goods74909Other professional, scientific and technical activities n.e.c.74999Other professional, scientific and technical activities n.e.c.27900Manufacture of other electrical equipment27900Manufacture of other electrical equipment
Joint committees (2)
- 100
- 200
Contacts
2 public details availableLog in to view
Signals
ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 11 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||||||||||
| Revenue | 12,5 M € | +21.8% | 10,2 M € | +11.9% | 9,2 M € | +24.2% | 7,4 M € | +12.4% | 6,6 M € | +13.8% | 5,8 M € | +2.9% | 5,6 M € | +0.9% | 5,6 M € | +1.3% | 5,5 M € | +24.4% | 4,4 M € | +1082% | 373 k € |
| EBITDA | 962,1 k € | +541% | 150 k € | -76.2% | 630,8 k € | -34.9% | 969 k € | +69.3% | 572,3 k € | +53.7% | 372,2 k € | +129% | 162,8 k € | +372% | -59,8 k € | -129% | 203,2 k € | +40.4% | 144,7 k € | +258% | -91,7 k € |
| Operating result | 268,2 k € | +156% | -476 k € | -3953% | 12,4 k € | -96.0% | 312,4 k € | +420% | -97,5 k € | +57.4% | -228,9 k € | +26.6% | -311,7 k € | +25.8% | -420,1 k € | -20375% | 2,1 k € | +104% | -50,6 k € | +58.7% | -122,3 k € |
| Net result | 129,1 k € | +121% | -619,1 k € | -10293% | -6 k € | -102% | 279,5 k € | +707% | -46 k € | +70.3% | -155,2 k € | +56.4% | -355,7 k € | -3.3% | -344,2 k € | -638% | 63,9 k € | +265% | -38,7 k € | +69.6% | -127,2 k € |
| Balance sheet | |||||||||||||||||||||
| Equity | 3,6 M € | +3.7% | 3,4 M € | -11.4% | 3,9 M € | -0.2% | 3,9 M € | +7.7% | 3,6 M € | +32.4% | 2,7 M € | -7.9% | 3 M € | +98.6% | 1,5 M € | -22.2% | 1,9 M € | +5.0% | 1,8 M € | +304% | 452,3 k € |
| Total assets | 8 M € | -5.1% | 8,4 M € | +34.3% | 6,3 M € | -12.6% | 7,2 M € | +17.9% | 6,1 M € | +10.2% | 5,5 M € | +0.3% | 5,5 M € | +11.6% | 4,9 M € | +13.7% | 4,3 M € | +13.5% | 3,8 M € | +276% | 1 M € |
| Cash | 231,6 k € | -10.1% | 257,6 k € | -26.7% | 351,6 k € | -66.7% | 1,1 M € | +16.1% | 907,9 k € | +557% | 138,1 k € | +85.5% | 74,4 k € | +26.0% | 59,1 k € | -68.1% | 185,4 k € | -0.5% | 186,3 k € | -30.0% | 266,3 k € |
| Debts | 3,9 M € | -14.1% | 4,6 M € | +121% | 2,1 M € | -26.7% | 2,8 M € | +19.7% | 2,4 M € | -15.7% | 2,8 M € | +10.0% | 2,5 M € | -26.0% | 3,4 M € | +41.9% | 2,4 M € | +21.3% | 2 M € | +253% | 564,5 k € |
| Other | |||||||||||||||||||||
| Workforce | 25,0 ETP | -2.3% | 25,6 ETP | +13.3% | 22,6 ETP | +10.2% | 20,5 ETP | +10.2% | 18,6 ETP | +13.4% | 16,4 ETP | +37.8% | 11,9 ETP | +5.3% | 11,3 ETP | +32.9% | 8,5 ETP | +51.8% | 5,6 ETP | +211% | 1,8 ETP |
Estimate
Indicative valuation
As an indication, this company is worth
between 1 M€ and 2,5 M€
See the valuationGovernance
Board of directors
Seen on filing of 30/06/2025 · 7 active · 13 ended
Active mandates
Active
Active
ANDRE LUXEN
ActiveActive
BIOINNOVAS SA
ActiveActive
Active
Ended mandates
At this address
Other companies at this address
| Company | CBE no. |
|---|---|
EAGLE HOLDING● Active | 1040.465.055 |
Financials
Annual accounts
Full financial information
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/07/2024 | 01/07/2023 | 01/07/2022 | 01/07/2021 | 01/07/2020 | 01/07/2019 |
| Closing of the financial year | 30/06/2025 | 30/06/2024 | 30/06/2023 | 30/06/2022 | 30/06/2021 | 30/06/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 28/11/2025 | 18/11/2024 | 17/01/2024 | 29/12/2022 | 30/11/2021 | 20/09/2021 |
| General meeting | 12/11/2025 | 12/11/2024 | 14/11/2023 | 08/11/2022 | 09/11/2021 | 10/11/2020 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
12 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 30/06/2025 | 12/11/2025 | 28/11/2025 | French | |
| Abridged model | 30/06/2024 | 12/11/2024 | 18/11/2024 | French | |
| Abridged model | 30/06/2023 | 14/11/2023 | 17/01/2024 | French | |
| Abridged model | 30/06/2022 | 08/11/2022 | 29/12/2022 | French | |
| Abridged model | 30/06/2021 | 09/11/2021 | 30/11/2021 | French | |
| Abridged modelCorrection | 30/06/2020 | 10/11/2020 | 20/09/2021 | French | |
| Abridged model | 30/06/2020 | 10/11/2020 | 14/01/2021 | French | |
| Abridged model | 30/06/2019 | 12/11/2019 | 28/11/2019 | French | |
| Abridged model | 30/06/2018 | 13/11/2018 | 22/11/2018 | French | |
| Abridged model | 30/06/2017 | 14/11/2017 | 19/12/2017 | French | |
| Abridged model | 30/06/2016 | 08/11/2016 | 19/01/2017 | French | |
| Abridged model | 30/06/2015 | 10/11/2015 | 13/01/2016 | French |
Valuation
Estimate
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 1 M€ and 2,5 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Governance
Board of directors
Seen on filing of 30/06/2025 · 7 active · 13 ended
Active mandates
Active
Active
ANDRE LUXEN
ActiveActive
BIOINNOVAS SA
ActiveActive
Active
Ended mandates
Shareholders
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette
Belgian Official Gazette publications
- Mandates11/09/2026Démission et nomination administrateurs
- Mandates09/02/2026SIEGE SOCIAL - DEMISSIONS, NOMINATIONS
- Mandates20/11/2025DEMISSIONS, NOMINATIONS
- Capital / shares18/04/2024CAPITAL, ACTIONS
- Mandates21/03/2022DEMISSIONS, NOMINATIONS
- Mandates23/12/2021DEMISSIONS, NOMINATIONS
- Mandates07/06/2021STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
- Capital / shares13/01/2021STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, ) - CAPITAL, ACTIONS
Source: Belgian Official Gazette
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025129,1 k €↑
- 2024Annual accounts 2024-619,1 k €↓
- 2023Annual accounts 2023-6 k €↓
- 2022Annual accounts 2022279,5 k €↑
- 2021Annual accounts 2021-46 k €↑
- 2020Annual accounts 2020-155,2 k €↑
- 2019Annual accounts 2019-355,7 k €↓
- 2018Annual accounts 2018-344,2 k €↓
- 2017Annual accounts 201763,9 k €↑
- 2016Annual accounts 2016-38,7 k €↑
- 2015Annual accounts 2015-127,2 k €
- 02/05/2014IncorporationPublic limited company